August 6, 2025

In a surprising move, the US Department of Health and Human Services (HHS) has revealed plans to cancel $500 million in funding for mRNA vaccines specifically targeting respiratory viruses, including those causing flu and COVID-19. HHS Secretary Robert F. Kennedy Jr. stated that the decision is rooted in concerns about the safety and effectiveness of mRNA technology in combating respiratory infections. This announcement comes as COVID-19 cases are experiencing an uptick across the country. Kennedy, who is known for his skeptical views on vaccines, emphasized that mRNA vaccines pose more risks than benefits. He claimed that the science behind these vaccines indicates they do not effectively protect against upper respiratory infections such as COVID-19 and the flu. This perspective has sparked significant debate among healthcare professionals, many of whom have criticized Kennedy for his long-standing doubts concerning vaccine safety and efficacy. According to HHS, the termination of funding will affect 22 federal contracts linked to mRNA vaccine development, including projects from prominent pharmaceutical companies such as Pfizer, Sanofi Pasteur, and Moderna. The department has chosen to retain some late-stage projects to safeguard previous taxpayer investments, but many proposals aimed at fighting COVID-19 will be scrapped entirely. Kennedy expressed that the shift in focus would move towards developing 'safer, broader vaccine platforms' that would be resilient against viral mutations. He further asserted that mRNA vaccines might actually contribute to encouraging new mutations of COVID-19, potentially prolonging pandemic scenarios as the virus evolves to evade vaccine-induced immune responses. Health experts have challenged Kennedy's assertions. They contend that viruses naturally mutate irrespective of vaccine presence. Peter Lurie, a former official with the US Food and Drug Administration (FDA), suggested that the decision represents a significant reversal for the US, implying a rejection of a promising method for ensuring public health in future pandemics. The development of mRNA vaccines has played a critical role in mitigating the impact of COVID-19, contributing to saved lives and a notable reduction in transmission rates during the pandemic. As the HHS announced the funding cuts, it also revealed that certain projects involving Moderna's bird flu vaccine would be halted, alongside contract terminations with Emory University and changes affecting ongoing agreements with CSL Seqirus. Other collaborations with Pfizer, Sanofi, and AstraZeneca are also subject to review. In the wake of these announcements, Moderna responded, clarifying that it currently lacks any active collaborations with the Biomedical Advanced Research and Development Authority (BARDA), which is part of HHS. AstraZeneca did not provide immediate comment on the funding cuts, and other involved companies did not respond to inquiries for their reactions. The timing of this funding cut is particularly controversial, with some supporters of Kennedy expressing frustration at the continued authorization of mRNA vaccines by the FDA, despite ongoing safety evaluations. Under Kennedy's leadership, the HHS has expressed intentions to focus future efforts on vaccine technologies that can adapt more successfully to evolving viral strains. As public health officials gear up for a potentially challenging flu season compounded by rising COVID-19 infections, the implications of HHS's funding decisions remain to be seen in the context of overall health system preparedness, vaccine availability, and public trust in vaccination efforts. As debates surrounding the safety of mRNA vaccines remain heated, both proponents and critics of these technologies are closely monitoring the situation.

Read More at Economictimes →

Tags: Mrna vaccines, Hhs, Robert f. kennedy jr., Covid-19, Funding cut,